Selling Stockholder Registers 2 Million Shares for Resale Amidst Nasdaq Delisting Threat and Going Concern

summarizeZusammenfassung

This 424B3 filing registers 2 million shares of common stock for resale by Hexstone Capital LLC, an institutional investor. This represents approximately 15% of the company's currently outstanding shares and will create substantial selling pressure and dilution without providing any direct capital to Propanc Biopharma. The shares originate from a private placement of Series C Preferred Stock and warrants with highly dilutive conversion terms (85% of the lowest trading price). This event is particularly critical given the company's recent Nasdaq non-compliance notice for minimum bid price and its explicit disclosure of substantial doubt about its ability to continue as a going concern. The ongoing liquidation by a major investor, coupled with the company's dire financial state, signals significant challenges ahead for its stock price and operational viability.

check_boxSchlusselereignisse

• Selling Stockholder Resale

  Hexstone Capital LLC is registering 2 million shares of common stock for resale, representing approximately 15% of the company's currently outstanding shares.

• No Company Proceeds

  Propanc Biopharma, Inc. will not receive any proceeds from the sale of these shares by the selling stockholder.

• Highly Dilutive Financing Terms

  The shares originate from Series C Preferred Stock and warrants convertible at a deep discount (85% of lowest trading price), indicating a highly dilutive financing structure.

• Financial Distress Context

  This resale occurs while the company faces a Nasdaq delisting notice (issued on 2026-01-07) and has expressed substantial doubt about its ability to continue as a going concern.

auto_awesomeAnalyse

This 424B3 filing registers 2 million shares of common stock for resale by Hexstone Capital LLC, an institutional investor. This represents approximately 15% of the company's currently outstanding shares and will create substantial selling pressure and dilution without providing any direct capital to Propanc Biopharma. The shares originate from a private placement of Series C Preferred Stock and warrants with highly dilutive conversion terms (85% of the lowest trading price). This event is particularly critical given the company's recent Nasdaq non-compliance notice for minimum bid price and its explicit disclosure of substantial doubt about its ability to continue as a going concern. The ongoing liquidation by a major investor, coupled with the company's dire financial state, signals significant challenges ahead for its stock price and operational viability.